BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
InnoCare Pharma Ltd. (9969.HK; 688428.SH) said on Thursday its revenue rose 37% last year to 1.01 billion yuan ($138 million), fueled by strong gains for Orelabrutinib, its drug used to…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
- DPC Dash serves up banner 2024 topped with milestones
- Horizon’s lead grows in smart driving race with new product rollouts
- Dingdong rings up strong end to 2024, but warns of turbulence ahead
- After profit plunge in 2024, Maoyan spotlights strong start to 2025
